CANCER DIGEST – Mar. 17, 2018 – The Centers for Medicare & Medicaid Services (CMS) announced on Mar. 16 that Medicare will cover genetic testing needed to match cancer patients with targeted immunotherapies. Specifically Medicare will cover Next Generation Sequencing (NGS) for patients with advanced cancer that has spread or has relapsed or fails to respond to other therapies.